



## Pulmonary Arterial Hypertension (PAH) Medicine Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-28	117	PDF
<b>Single User</b>	<b>Multi User</b>	<b>Enterprise</b>	
<b>USD 2,950</b>	<b>USD 4,430</b>	<b>USD 5,900</b>	

### Description

The global Pulmonary Arterial Hypertension (PAH) Medicine market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Pulmonary Arterial Hypertension (PAH) Medicine is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Pulmonary Arterial Hypertension (PAH) Medicine is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Pulmonary Arterial Hypertension (PAH) Medicine is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine include Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics Corporation, Pfizer and Eli Lilly, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

### Report Scope

This report quantifies the global Pulmonary Arterial Hypertension (PAH) Medicine market in terms of revenue (US\$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

### Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Pulmonary Arterial Hypertension (PAH) Medicine Market by Company

Actelion Pharmaceuticals

Gilead Sciences

United Therapeutics Corporation

Pfizer

Eli Lilly

## **Pulmonary Arterial Hypertension (PAH) Medicine Segment by Type**

Calcium Channel Blockers

Novel Targeted Drugs

Other

## **Pulmonary Arterial Hypertension (PAH) Medicine Segment by Application**

Secondary Pulmonary Hypertension (SPH)

Primary Pulmonary Hypertension (PPH)

## **Pulmonary Arterial Hypertension (PAH) Medicine Segment by Region**

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

## **Key Drivers & Barriers**

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

## **Reasons to Buy This Report**

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Arterial Hypertension (PAH) Medicine market, and introduces in detail the market

share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Arterial Hypertension (PAH) Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Arterial Hypertension (PAH) Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

## **Chapter Outline**

### **Chapter 1:**

Research objectives, research methods, data sources, data cross-validation;

### **Chapter 2:**

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

### **Chapter 3:**

Detailed analysis of Pulmonary Arterial Hypertension (PAH) Medicine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

### **Chapter 4:**

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

### **Chapter 5:**

Production/output, value of Pulmonary Arterial Hypertension (PAH) Medicine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

### **Chapter 6:**

Consumption of Pulmonary Arterial Hypertension (PAH) Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

### **Chapter 7:**

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

### **Chapter 8:**

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

**Chapter 9:**

Analysis of industrial chain, including the upstream and downstream of the industry.

**Chapter 10:**

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

**Chapter 11:**

The main points and conclusions of the report.

# Table of Contents

---

## 1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
  - 1.5.1 Secondary Sources
  - 1.5.2 Primary Sources

---

## 2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
  - 2.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size (2021-2032)
  - 2.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (2021-2032)
  - 2.2.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Average Price (2021-2032)
- 2.3 Pulmonary Arterial Hypertension (PAH) Medicine by Type
  - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
  - 2.3.2 Calcium Channel Blockers
  - 2.3.3 Novel Targeted Drugs
  - 2.3.4 Other
- 2.4 Pulmonary Arterial Hypertension (PAH) Medicine by Application
  - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  - 2.4.2 Secondary Pulmonary Hypertension (SPH)
  - 2.4.3 Primary Pulmonary Hypertension (PPH)

---

## 3 Market Competitive Landscape by Manufacturers

- 3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue of Manufacturers (2021-2026)
- 3.4 Global Pulmonary Arterial Hypertension (PAH) Medicine Average Price by Manufacturers (2021-2026)
- 3.5 Global Pulmonary Arterial Hypertension (PAH) Medicine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine, Product Type & Application
- 3.8 Global Manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine, Established Date
- 3.9 Global Pulmonary Arterial Hypertension (PAH) Medicine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

---

## 4 Manufacturers Profiled

- 4.1 Actelion Pharmaceuticals
  - 4.1.1 Actelion Pharmaceuticals Company Information
  - 4.1.2 Actelion Pharmaceuticals Business Overview
  - 4.1.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2021-2026)
  - 4.1.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
  - 4.1.5 Actelion Pharmaceuticals Recent Developments

## 4.2 Gilead Sciences

4.2.1 Gilead Sciences Company Information

4.2.2 Gilead Sciences Business Overview

4.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2021-2026)

4.2.4 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

4.2.5 Gilead Sciences Recent Developments

## 4.3 United Therapeutics Corporation

4.3.1 United Therapeutics Corporation Company Information

4.3.2 United Therapeutics Corporation Business Overview

4.3.3 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2021-2026)

4.3.4 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

4.3.5 United Therapeutics Corporation Recent Developments

## 4.4 Pfizer

4.4.1 Pfizer Company Information

4.4.2 Pfizer Business Overview

4.4.3 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2021-2026)

4.4.4 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

4.4.5 Pfizer Recent Developments

## 4.5 Eli Lilly

4.5.1 Eli Lilly Company Information

4.5.2 Eli Lilly Business Overview

4.5.3 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2021-2026)

4.5.4 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

4.5.5 Eli Lilly Recent Developments

---

## 5 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Scenario by Region

5.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Region: 2021 VS 2025 VS 2032

5.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region: 2021-2032

5.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region: 2021-2026

5.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region: 2027-2032

5.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region: 2021-2032

5.3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region: 2021-2026

5.3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region: 2027-2032

5.4 North America Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country

5.4.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2021 VS 2025 VS 2032

5.4.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2032)

5.4.3 North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2021-2032)

5.4.4 United States

5.4.5 Canada

5.5 Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country

5.5.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2021 VS 2025 VS 2032

5.5.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2032)

5.5.3 Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2021-2032)

5.5.4 Germany

5.5.5 France

5.5.6 U.K.

5.5.7 Italy

5.5.8 Netherlands

5.5.9 Nordic Countries

5.6 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country

5.6.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2021 VS 2025 VS 2032

5.6.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2032)

5.6.3 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2021-2032)

5.6.4 China

5.6.5 Japan

5.6.6 South Korea

5.6.7 India

5.6.8 Australia

5.6.9 China Taiwan

5.6.10 Southeast Asia

5.7 South America Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country

5.7.1 South America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2021 VS 2025 VS 2032

5.7.2 South America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2032)

5.7.3 South America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2021-2032)

5.7.4 Mexico

5.7.5 Brazil

5.7.6 Argentina

5.7.7 Colombia

5.8 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country

5.8.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2021 VS 2025 VS 2032

5.8.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2032)

5.8.3 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2021-2032)

5.8.4 Turkey

5.8.5 Saudi Arabia

5.8.6 UAE

---

## 6 Segment by Type

6.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2032)

6.1.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2032) & (K Units)

6.1.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2021-2032)

6.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type (2021-2032)

6.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2032) & (US\$ Million)

6.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type (2021-2032)

6.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Type (2021-2032)

---

## 7 Segment by Application

7.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2032)

7.1.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2032) & (K Units)

7.1.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2021-2032)

7.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application (2021-2032)

7.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2032) & (US\$ Million)

7.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application (2021-2032)

7.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Application (2021-2032)

---

## 8 Value Chain and Sales Channels Analysis of the Market

8.1 Pulmonary Arterial Hypertension (PAH) Medicine Value Chain Analysis

8.1.1 Pulmonary Arterial Hypertension (PAH) Medicine Key Raw Materials

8.1.2 Raw Materials Key Suppliers

8.1.3 Pulmonary Arterial Hypertension (PAH) Medicine Production Mode & Process

8.2 Pulmonary Arterial Hypertension (PAH) Medicine Sales Channels Analysis

8.2.1 Direct Comparison with Distribution Share

8.2.2 Pulmonary Arterial Hypertension (PAH) Medicine Distributors

8.2.3 Pulmonary Arterial Hypertension (PAH) Medicine Customers

---

## **9 Global Pulmonary Arterial Hypertension (PAH) Medicine Analyzing Market Dynamics**

9.1 Pulmonary Arterial Hypertension (PAH) Medicine Industry Trends

9.2 Pulmonary Arterial Hypertension (PAH) Medicine Industry Drivers

9.3 Pulmonary Arterial Hypertension (PAH) Medicine Industry Opportunities and Challenges

9.4 Pulmonary Arterial Hypertension (PAH) Medicine Industry Restraints

---

## **10 Report Conclusion**

---

## **11 Disclaimer**

## List of Tables and Figures

---

### List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Pulmonary Arterial Hypertension (PAH) Medicine Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units) of Manufacturers (2021-2026)
- Table 7: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue of Manufacturers (2021-2026)
- Table 9: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Pulmonary Arterial Hypertension (PAH) Medicine Average Price (US\$/Unit) of Manufacturers (2021-2026)
- Table 11: Global Pulmonary Arterial Hypertension (PAH) Medicine Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine, Product Type & Application
- Table 14: Global Pulmonary Arterial Hypertension (PAH) Medicine Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Pulmonary Arterial Hypertension (PAH) Medicine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: Actelion Pharmaceuticals Company Information
- Table 19: Actelion Pharmaceuticals Business Overview
- Table 20: Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 21: Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
- Table 22: Actelion Pharmaceuticals Recent Developments
- Table 23: Gilead Sciences Company Information
- Table 24: Gilead Sciences Business Overview
- Table 25: Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 26: Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
- Table 27: Gilead Sciences Recent Developments
- Table 28: United Therapeutics Corporation Company Information
- Table 29: United Therapeutics Corporation Business Overview
- Table 30: United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 31: United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
- Table 32: United Therapeutics Corporation Recent Developments
- Table 33: Pfizer Company Information
- Table 34: Pfizer Business Overview
- Table 35: Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 36: Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
- Table 37: Pfizer Recent Developments
- Table 38: Eli Lilly Company Information
- Table 39: Eli Lilly Business Overview
- Table 40: Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 41: Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
- Table 42: Eli Lilly Recent Developments
- Table 43: Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 44: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2021-2026) & (K Units)
- Table 45: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region (2021-2026)
- Table 46: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2027-2032) & (K Units)

- Table 47: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region (2027-2032)
- Table 48: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2021-2026) & (US\$ Million)
- Table 49: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Region (2021-2026)
- Table 50: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2027-2032) & (US\$ Million)
- Table 51: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Region (2027-2032)
- Table 52: North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 53: North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026) & (K Units)
- Table 54: North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2027-2032) & (K Units)
- Table 55: North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2021-2026) & (US\$ Million)
- Table 56: North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2027-2032) & (US\$ Million)
- Table 57: Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 58: Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026) & (K Units)
- Table 59: Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2027-2032) & (K Units)
- Table 60: Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2021-2026) & (US\$ Million)
- Table 61: Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2027-2032) & (US\$ Million)
- Table 62: Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 63: Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026) & (K Units)
- Table 64: Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2027-2032) & (K Units)
- Table 65: Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2021-2026) & (US\$ Million)
- Table 66: Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2027-2032) & (US\$ Million)
- Table 67: South America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 68: South America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026) & (K Units)
- Table 69: South America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2027-2032) & (K Units)
- Table 70: South America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2021-2026) & (US\$ Million)
- Table 71: South America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2027-2032) & (US\$ Million)
- Table 72: Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 73: Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026) & (K Units)
- Table 74: Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2027-2032) & (K Units)
- Table 75: Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2021-2026) & (US\$ Million)
- Table 76: Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2027-2032) & (US\$ Million)
- Table 77: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2026) & (K Units)
- Table 78: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2027-2032) & (K Units)
- Table 79: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2021-2026)
- Table 80: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2027-2032)
- Table 81: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type (2021-2026) & (US\$ Million)
- Table 82: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type (2027-2032) & (US\$ Million)
- Table 83: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type (2021-2026)
- Table 84: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type (2027-2032)
- Table 85: Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Type (2021-2026) & (US\$/Unit)
- Table 86: Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Type (2027-2032) & (US\$/Unit)
- Table 87: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2026) & (K Units)
- Table 88: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2027-2032) & (K Units)
- Table 89: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2021-2026)
- Table 90: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2027-2032)
- Table 91: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application (2021-2026) & (US\$ Million)
- Table 92: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application (2027-2032) & (US\$ Million)
- Table 93: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application (2021-2026)
- Table 94: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application (2027-2032)
- Table 95: Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Application (2021-2026) & (US\$/Unit)
- Table 96: Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Application (2027-2032) & (US\$/Unit)
- Table 97: Key Raw Materials
- Table 98: Raw Materials Key Suppliers
- Table 99: Pulmonary Arterial Hypertension (PAH) Medicine Distributors List
- Table 100: Pulmonary Arterial Hypertension (PAH) Medicine Customers List
- Table 101: Pulmonary Arterial Hypertension (PAH) Medicine Industry Trends
- Table 102: Pulmonary Arterial Hypertension (PAH) Medicine Industry Drivers
- Table 103: Pulmonary Arterial Hypertension (PAH) Medicine Industry Restraints
- Table 104: Authors List of This Report

## List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Pulmonary Arterial Hypertension (PAH) Medicine Product Image
- Figure 5: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (2021-2032) & (K Units)
- Figure 8: Global Pulmonary Arterial Hypertension (PAH) Medicine Average Price (US\$/Unit) & (2021-2032)
- Figure 9: Calcium Channel Blockers Product Image
- Figure 10: Novel Targeted Drugs Product Image
- Figure 11: Other Product Image
- Figure 12: Secondary Pulmonary Hypertension (SPH) Product Image
- Figure 13: Primary Pulmonary Hypertension (PPH) Product Image
- Figure 14: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Manufacturers in 2025
- Figure 15: Global Manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine, Manufacturing Sites & Headquarters
- Figure 16: Global Top 5 and 10 Pulmonary Arterial Hypertension (PAH) Medicine Players Market Share by Revenue in 2025
- Figure 17: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 18: Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 19: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region in 2025
- Figure 20: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region in 2025
- Figure 21: North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country in 2025
- Figure 22: North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2021-2032)
- Figure 23: North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2021-2032)
- Figure 24: United States Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 25: Canada Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 26: Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country in 2025
- Figure 27: Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2021-2032)
- Figure 28: Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2021-2032)
- Figure 29: Germany Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 30: France Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 31: U.K. Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 32: Italy Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 33: Netherlands Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 34: Nordic Countries Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 35: Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country in 2025
- Figure 36: Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2021-2032)
- Figure 37: Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2021-2032)
- Figure 38: China Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Japan Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: South Korea Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 41: India Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 42: Australia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 43: China Taiwan Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 44: Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 45: Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 46: South America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country in 2025
- Figure 47: South America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2021-2032)
- Figure 48: South America Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2021-2032)
- Figure 49: Mexico Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: Brazil Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: Argentina Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 52: Colombia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 53: Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country in 2025
- Figure 54: Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2021-2032)
- Figure 55: Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2021-2032)
- Figure 56: Turkey Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)

- Figure 57: Saudi Arabia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 58: UAE Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 59: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2021-2032)
- Figure 60: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type (2021-2032)
- Figure 61: Global Pulmonary Arterial Hypertension (PAH) Medicine Price (US\$/Unit) by Type (2021-2032)
- Figure 62: Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2021-2032)
- Figure 63: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application (2021-2032)
- Figure 64: Global Pulmonary Arterial Hypertension (PAH) Medicine Price (US\$/Unit) by Application (2021-2032)
- Figure 65: Pulmonary Arterial Hypertension (PAH) Medicine Value Chain
- Figure 66: Pulmonary Arterial Hypertension (PAH) Medicine Production Mode & Process
- Figure 67: Direct Comparison with Distribution Share
- Figure 68: Distributors Profiles
- Figure 69: Pulmonary Arterial Hypertension (PAH) Medicine Industry Opportunities and Challenges